A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
Sweden
Study Type
Interventional
Intervention
Spirometry, PEF measurements and diary cards to evaluate control of Asthma
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- written informed consent
- 18 years or above
- able to fill in questionnaires and perform PEF measurements
- asthma diagnosis and prescribed SERETIDE or SYMBICORT, either regular treatment using SERETIDE in a stable dosing and short acting B2 agonists as needed, or maintenance treatment with SYMBICORT but also using same inhaler SYMBICORT as needed
Exclusion Criteria:
- no other lung disease
- neurological disease with psychological handicap
- cerebro-vascular disease with handicap
- un-stable cancer
- known or planned pregnancy during the time of the study
- subjects who have serious uncontrolled disease
Sites / Locations
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Stable dosing with SERETIDE, short acting B-2agonist as needed
Maintenance treatment with SYMBICORT and SYMBICORT as needed
Arm Description
Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
Outcomes
Primary Outcome Measures
asthma control based on GINA guidelines from 2007.
Secondary Outcome Measures
Quality of Life, Health economics and exacerbations
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00858286
Brief Title
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
Official Title
Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies, regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed, or maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed.
Detailed Description
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies. No therapy intervention is made with existing prescribed medications (SERETIDE or SYMBICORT), but evaluations outside standard care is made by evluations with diary cards, questionnaires, PEF evaluations and spirometry which is regarded as the intervention by the Swedish Authorities.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
56 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stable dosing with SERETIDE, short acting B-2agonist as needed
Arm Type
Experimental
Arm Description
Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
Arm Title
Maintenance treatment with SYMBICORT and SYMBICORT as needed
Arm Type
Experimental
Arm Description
Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
Intervention Type
Other
Intervention Name(s)
Spirometry, PEF measurements and diary cards to evaluate control of Asthma
Intervention Description
No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
Primary Outcome Measure Information:
Title
asthma control based on GINA guidelines from 2007.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Quality of Life, Health economics and exacerbations
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
written informed consent
18 years or above
able to fill in questionnaires and perform PEF measurements
asthma diagnosis and prescribed SERETIDE or SYMBICORT, either regular treatment using SERETIDE in a stable dosing and short acting B2 agonists as needed, or maintenance treatment with SYMBICORT but also using same inhaler SYMBICORT as needed
Exclusion Criteria:
no other lung disease
neurological disease with psychological handicap
cerebro-vascular disease with handicap
un-stable cancer
known or planned pregnancy during the time of the study
subjects who have serious uncontrolled disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Stockholm
ZIP/Postal Code
SE-171 77
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
We'll reach out to this number within 24 hrs